These findings highlight the significant overexpression of galectin-8 in both drug-resistant and TNBC cells, suggesting that targeting galectin-8 could be a promising approach for overcoming resistance in TNBC and improving treatment outcomes for patients with aggressive breast cancer subtypes. Here, LGALS8 is linked to breast carcinoma.